Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $6.96K | $702K | $483K | $356K | $970K | $152K | $0.00 | $296K |
| Revenue growth | — | — | — | 9988.0% | -31.2% | -26.3% | 172.6% | -84.3% | -100.0% | — |
| Gross profit | -$32.00 | — | -$178K | $682K | $464K | $351K | $683K | -$150K | $509K | — |
| Gross margin | — | — | -2563.6% | 97.1% | 96.1% | 98.6% | 70.5% | -98.1% | — | — |
| Operating income | -$11.0M | -$4.14M | -$2.78M | -$3.46M | -$8.51M | -$11.7M | -$15.1M | -$6.77M | -$4.71M | -$7.15M |
| Operating margin | — | — | -40031.1% | -492.9% | -1760.9% | -3290.1% | -1558.5% | -4439.2% | — | -2416.0% |
| Net income | -$11.0M | -$4.24M | -$6.06M | -$3.93M | -$10.6M | -$12.8M | -$16.4M | -$7.79M | -$4.90M | -$7.91M |
| Net margin | — | — | -87184.2% | -560.5% | -2193.1% | -3608.5% | -1693.5% | -5109.3% | — | -2671.8% |
| EPS (diluted) | -$0.06 | -$0.02 | -$0.02 | -$0.21 | -$0.50 | -$0.51 | -$5.19 | -$1.80 | -$0.42 | -$0.39 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.47M | -$1.49M | -$901K | -$3.13M | -$4.56M | -$7.60M | -$7.40M | -$4.19M | -$1.81M | -$2.99M |
| Capital expenditures | — | — | — | — | — | $17.5K | $120K | $21.2K | — | — |
| Free cash flow | — | — | — | — | — | -$7.62M | -$7.52M | -$4.21M | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $18.6K | $93.3K | $227K | $144K | $4.27M | $5.83M | $85.3K | $60.2K | $248K | $681K |
| Total assets | $177K | $2.64M | $5.94M | $6.93M | $11.6M | $13.7M | $9.58M | $7.78M | $7.54M | $21.1M |
| Total liabilities | $6.56M | $4.40M | $11.3M | $7.05M | $8.94M | $4.83M | $6.34M | $6.53M | $6.82M | $7.76M |
| Shareholders' equity | -$6.52M | -$1.76M | -$5.66M | -$151K | $3.44M | $8.84M | $3.10M | $1.55M | $1.23M | $11.1M |
| Retained earnings | -$11.3M | -$15.8M | -$12.2M | -$15.9M | -$25.6M | -$38.5M | -$54.9M | -$64.0M | -$68.9M | -$76.9M |
| Shares (wtd avg diluted) | 194M | 213M | 214M | 19.5M | 19.7M | 25.1M | 3.17M | 4.34M | 11.7M | 20.1M |
Every figure is extracted from ABVC BIOPHARMA, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.